终末期患者呼吸困难的临床管理综述
该综述聚焦晚期终末期患者(含呼吸、心脏或癌症相关疾病)呼吸困难的机制与管理,指出与疼痛相比,呼吸困难的对症治疗在临床实践和文献中关注较少,尤其在合并急性呼吸衰竭时因多数药物与非药物研究排除此类患者。文章汇总相关临床试验证据,讨论可用于这些患者的药物与非药物干预措施。
要点
- 终末期呼吸困难由多种机制介导,受既往经历、价值观、情绪和信念影响。
- 与疼痛相比,呼吸困难的对症治疗在临床实践和文献中关注相对不足。
- 合并急性呼吸衰竭的终末期患者常被药物与非药物研究排除,证据有限。
核心结论
- 终末期患者呼吸困难可能变得难以忍受,需关注其药物与非药物干预证据。
研究设计与样本
- 综述,聚焦晚期终末期患者呼吸困难管理,汇总药物与非药物干预的临床试验证据。
主要发现
- 呼吸困难的发生涉及多种机制,其感知受既往经历、价值观、情绪和信念影响。
- 与疼痛相比,呼吸困难的对症治疗在临床实践和医学文献中关注相对较少。
- 多数药物与非药物治疗呼吸窘迫的研究排除了合并急性呼吸衰竭的患者。
- ICU 患者死亡质量评估一致显示,家属认为仅少数患者在生命终末呼吸舒适。
临床怎么用
- 对终末期患者应重视呼吸困难的对症管理,而非仅关注疼痛。
- 合并急性呼吸衰竭的终末期患者证据有限,临床决策需个体化。
局限性
- 多数药物与非药物研究排除合并急性呼吸衰竭的患者,证据外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The genesis of dyspnea involves the activation of several mechanisms that are mediated and perceived depending on previous experiences, values, emotions, and beliefs. Breathlessness may become unbearable, especially in patients who are terminally ill, whether afflicted by respiratory-, cardiac-, or cancer-related disorders, because of a final stage of a chronic process, an acute event, or both. Compared with pain, palliation of dyspnea has received relatively little attention in clinical practice and the medical literature. This is particularly true when the breathlessness is associated with acute respiratory failure because most of the studies on pharmacologic and nonpharmacologic treatments of respiratory distress have excluded such patients. Assessments of the quality of dying for patients in an ICU consistently show that few patients are considered by family members to breathe comfortably at the end of their life. This review focuses on the management of dyspnea in patients with advanced terminal illness, summarizing clinical trial evidence on pharmacologic and nonpharmacologic interventions available for these patients.
引用
- Pisani L, Hill NS, Pacilli AMG, et al. Management of Dyspnea in the Terminally Ill. Chest. 2018. PMID: 29679597. doi:10.1016/j.chest.2018.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。